결합조직질환 시장 규모, 점유율, 동향 분석 보고서 : 질환별, 의약품별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Connective Tissue Disease Market Size, Share & Trends Analysis Report By Disease (Rheumatoid Arthritis), By Drug (Pharmaceuticals), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

결합조직질환 시장 동향

결합조직질환 세계 시장 규모는 2023년 240억 4,000만 달러로 추정되며, 2024년부터 2030년까지 연평균 6.1%의 성장률을 보일 것으로 예상됩니다. 이러한 성장은 이러한 질환의 유병률 증가, 진단 기술 및 치료 접근법의 발전, 효과적인 치료에 대한 수요 증가에 기인합니다. 류마티스 관절염, 전신성 홍반성 루푸스, 강피증과 같은 자가면역질환 및 류마티스 질환의 유병률 증가는 결합조직질환(CTD) 시장의 성장을 촉진하는 중요한 요인입니다. 미국 루푸스 재단에 따르면, 약 150만 명의 미국인과 500만 명 이상의 사람들이 루푸스 질환을 앓고 있습니다.

또한, 전 세계 고령화도 시장 촉진요인 중 하나입니다. 나이가 들면 류마티스 관절염이나 강피증과 같은 자가면역질환에 걸리기 쉽습니다. 이러한 인구통계학적 추세는 결합조직질환을 앓고 있는 노인 환자들의 특별한 요구를 충족시키기 위해 조정된 혁신적 트렌드와 개인 맞춤형 의료에 대한 수요를 촉진하고 있습니다. 제약사들은 이러한 질환을 타깃으로 하는 새로운 치료법을 도입하기 위해 연구개발에 투자하고 있습니다.

또한, 정밀의료와 바이오마커 탐색의 기술 발전은 결합조직질환의 진단 및 치료 환경을 변화시키고 있습니다. 자가 면역 반응에 관여하는 특정 경로를 조절하는 것을 목표로 하는 표적 치료제의 출현은 시장 성장을 촉진하고 있습니다. 예를 들어, CTD의 병인에 관여하는 주요 분자를 표적으로 삼는 단클론항체와 같은 생물학적 제제가 개발되어 환자에게 보다 효과적이고 안전한 치료 옵션을 제공하고 있습니다. 이러한 혁신은 환자의 치료 결과와 삶의 질을 개선하는 맞춤형 솔루션을 제공함으로써 시장을 재편하고 있습니다.

결합조직질환 세계 시장 세분화 보고서

이 보고서는 2018년부터 2030년까지 세계, 지역 및 국가별 매출 성장을 예측하고 각 하위 부문의 최신 산업 동향 분석을 제공합니다. 이 조사에서 Grand View Research는 세계 결합조직질환 시장 보고서를 질병, 약물, 유통 채널 및 지역에 따라 다음과 같이 세분화했습니다.

• 결합조직질환 전망(매출액, 2018-2030년)
• 류마티스 관절염(RA)
• 전신성 홍반성 루푸스(SLE)
• 강피증
• 다발성 근염
• 피부 근염
• 쇼그렌 증후군
• 혼합 결합조직질환(MCTD)
• 미분화 결합조직질환(UCTD)
• 기타 결합조직질환
• 결합조직질환 치료제 전망(매출액, 2018-2030년)
• 의약품

비스테로이드성 항염증제(NSAIDs)

질병 조절 항류마티스제제(DMARDs)

코르티코스테로이드

기타 의약품

• 바이오의약품

생물학적 제제

TNF 억제제

IL-6 억제제

B 세포 억제제

T 세포 억제제

기타 생물학적 제제

바이오시밀러

• 결합조직병 유통 채널 전망(매출액, 2018-2030년)
• 병원 약국
• 소매 약국
• 온라인 약국
• 지역별 전망(매출액, 2018-2030년)
• 북미

미국

캐나다

멕시코

• 유럽

영국

독일

프랑스

이탈리아

스페인

덴마크

스웨덴

노르웨이

• 아시아태평양

일본

중국

인도

호주

한국

태국

• 라틴아메리카

브라질

아르헨티나

• 중동 및 아프리카

남아프리카공화국

사우디아라비아

아랍에미리트

쿠웨이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 결합조직질환 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 결합조직질환 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • 파이프라인 분석

제4장 결합조직질환 시장 : 질환 추정·동향 분석

• 세계의 결합조직질환 시장 : 질환 대시보드
• 세계의 결합조직질환 시장 : 질환 분석
• 질환별, 매출별, 세계의 결합조직질환 시장
• 류마티스 관절염(RA)
• 전신홍반루푸스(SLE)
• 경피증
• 다발성근염
• 피부근염
• 쇼그렌 증후군
• 혼합성 결합조직질환(MCTD)
• 미분화 결합조직질환(UCTD)
• 기타 결합조직질환

제5장 결합조직질환 시장 : 의약품 추정·동향 분석

• 세계의 결합조직질환 시장 : 의약품 대시보드
• 세계의 결합조직질환 시장 : 의약품 변동 분석
• 의약품별, 매출
• 의약품
• 바이오의약품

TNF 억제제 시장 추정과 예측 2018-2030년

IL-6 억제제 시장 추정과 예측 2018-2030년

B세포 억제제 시장 추정과 예측 2018-2030년

T세포 억제제 시장 추정과 예측 2018-2030년

기타 생물학적 제제 시장 추정과 예측 2018-2030년

• 바이오시밀러
  • 바이오시밀러 시장 추정과 예측 2018-2030년

제6장 결합조직질환 시장 : 유통 채널 추정·동향 분석

• 세계의 결합조직질환 시장 : 유통 채널 대시보드
• 세계의 결합조직질환 시장 : 유통 채널 변동 분석
• 유통 채널별, 매출
• 병원 약국
• 소매 약국
• 온라인 약국

제7장 결합조직질환 시장 : 질환, 의약품, 유통 채널별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018년에서 2030년 :
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 상황

• 기업/경쟁 분류
• 벤더 상황
  • List of key distributors and channel partners
  • Key customers
  • Key company market share analysis, 2023
  • AbbVie, Inc.
  • Amgen, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Lily
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • UCB SA

ksm

영문 목차

영문목차

Connective Tissue Disease Market Trends

The global connective tissue disease market size was estimated at USD 24.04 billion in 2023 and is expected to grow at a CAGR of 6.1% from 2024 to 2030. This growth is attributed to the increasing prevalence of these diseases, advancements in diagnostic techniques & treatment approaches, and growing demand for effective treatments. The rising incidence of autoimmune and rheumatic disorders, such as rheumatoid arthritis, systemic lupus erythematosus, and scleroderma, is a significant driver for the growth of the connective tissue disease (CTD) market. According to the Lupus Foundation of America,about 1.5 million Americans and more than five million people globally are affected by some type of lupus.

Moreover, the aging population worldwide is another significant driver for the growth of the market. As individuals age, they are more prone to developing autoimmune disorders such as rheumatoid arthritis and scleroderma, both of which fall under the category of connective tissue disease. This demographic trend fuels the demand for innovative therapies and personalized medicine approaches tailored to address the specific needs of elderly patients with connective tissue diseases. Pharmaceutical companies invest in research and development activities to introduce novel treatments targeting these conditions.

Furthermore, technological advancements in precision medicine and biomarker discovery are revolutionizing the diagnosis and treatment landscape for connective tissue diseases. The emergence of targeted therapies that aim to modulate specific pathways involved in autoimmune responses is propelling market growth. For instance, biologics such as monoclonal antibodies are being developed to target key molecules implicated in CTD pathogenesis, offering patients more effective and safer treatment options. These innovations are reshaping the market by providing personalized solutions that improve patient outcomes and quality of life.

Global Connective Tissue Disease Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global connective tissue disease market report on the basis of disease, drug, distribution channel, region:

• Connective Tissue Disease Outlook (Revenue, USD Million, 2018 - 2030)
• Rheumatoid Arthritis (RA)
• Systemic Lupus Erythematosus (SLE)
• Scleroderma
• Polymyositis
• Dermatomyositis
• Sjogren's Syndrome
• Mixed Connective Tissue Disease (MCTD)
• Undifferentiated Connective Tissue Disease (UCTD)
• Other connective tissue disease
• Connective Tissue Disease Drug Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceuticals

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Corticosteroids

Other Pharmaceuticals

• Biopharmaceuticals

Biologics

TNF Inhibitors

IL-6 Inhibitors

B-cell Inhibitors

T-cell Inhibitors

Other Biologics

Biosimilars

• Connective Tissue Disease Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

• Latin America

Brazil

Argentina

• Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease
  • 1.2.2. Drug
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease outlook
  • 2.2.2. Drug outlook
  • 2.2.3. Distribution Channel outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Connective Tissue Disease Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of connective tissue diseases
    • 3.2.1.2. Aging Population
    • 3.2.1.3. Technological advancements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High treatment cost
• 3.3. Connective Tissue Disease Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Connective Tissue Disease Market: Disease Estimates & Trend Analysis

• 4.1. Global Connective Tissue Disease Market: Disease Dashboard
• 4.2. Global Connective Tissue Disease Market: Disease Analysis
• 4.3. Global Connective Tissue Disease Market by Disease, Revenue
• 4.4. Rheumatoid Arthritis (RA)
  • 4.4.1. Rheumatoid Arthritis (RA) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Systemic Lupus Erythematosus (SLE)
  • 4.5.1. Systemic Lupus Erythematosus (SLE) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Scleroderma
  • 4.6.1. Scleroderma market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Polymyositis
  • 4.7.1. Polymyositis market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Dermatomyositis
  • 4.8.1. Dermatomyositis market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Sjogren's Syndrome
  • 4.9.1. Postpartum psychosis market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Mixed Connective Tissue Disease (MCTD)
  • 4.10.1. Mixed Connective Tissue Disease (MCTD) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Undifferentiated Connective Tissue Disease (UCTD)
  • 4.11.1. Undifferentiated Connective Tissue Disease (UCTD) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.12. Other connective tissue disease
  • 4.12.1. Other connective tissue disease market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Connective Tissue Disease Market: Drug Estimates & Trend Analysis

• 5.1. Global Connective Tissue Disease Market: Drug Dashboard
• 5.2. Global Connective Tissue Disease Market: Drug Movement Analysis
• 5.3. Global Connective Tissue Disease Market Estimates and Forecasts, By Drug, Revenue (USD Million)
• 5.4. Pharmaceuticals
  • 5.4.1. Pharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
    • 5.4.2.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    • 5.4.3.1. Disease-Modifying Anti-Rheumatic Drugs (DMARDs) market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Corticosteroids
    • 5.4.4.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Other Pharmaceuticals
    • 5.4.5.1. Other Pharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Biopharmaceuticals
  • 5.5.1. Biopharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Biologics
    • 5.5.2.1. Biologics market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2.2. TNF Inhibitors

5.5.2.2.1.1. TNF Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

• 5.5.2.3. IL-6 Inhibitors

5.5.2.3.1.1. IL-6 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

• 5.5.2.4. B-cell Inhibitors

5.5.2.4.1.1. B-cell Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

• 5.5.2.5. T-cell inhibitors

5.5.2.5.1.1. T-cell Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

• 5.5.2.6. Other Biologics

5.5.2.6.1.1. Other Biologics market estimates and forecasts 2018 to 2030 (USD Million)

• 5.6. Biosimilars
  • 5.6.1. Biosimilars market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Connective Tissue Disease Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global Connective Tissue Disease Market: Distribution Channel Dashboard
• 6.2. Global Connective Tissue Disease Market: Distribution Channel Movement Analysis
• 6.3. Global Connective Tissue Disease Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Connective Tissue Disease Market: Regional Estimates & Trend Analysis by Disease, Drug, and Distribution Channel

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Vendor Landscape
  • 8.2.1. List of key distributors and channel partners
  • 8.2.2. Key customers
  • 8.2.3. Key company market share analysis, 2023
  • 8.2.4. AbbVie, Inc.
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Amgen, Inc.
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. Boehringer Ingelheim International GmbH
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Bristol-Myers Squibb Company
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. F. Hoffmann-La Roche Ltd.
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Johnson & Johnson Services, Inc.
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. Lily
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product benchmarking
    • 8.2.10.4. Strategic initiatives
  • 8.2.11. Novartis AG
    • 8.2.11.1. Company overview
    • 8.2.11.2. Financial performance
    • 8.2.11.3. Product benchmarking
    • 8.2.11.4. Strategic initiatives
  • 8.2.12. Pfizer Inc.
    • 8.2.12.1. Company overview
    • 8.2.12.2. Financial performance
    • 8.2.12.3. Product benchmarking
    • 8.2.12.4. Strategic initiatives
  • 8.2.13. Regeneron Pharmaceuticals Inc.
    • 8.2.13.1. Company overview
    • 8.2.13.2. Financial performance
    • 8.2.13.3. Product benchmarking
    • 8.2.13.4. Strategic initiatives
  • 8.2.14. UCB S.A.
    • 8.2.14.1. Company overview
    • 8.2.14.2. Financial performance
    • 8.2.14.3. Product benchmarking
    • 8.2.14.4. Strategic initiatives